Flossbach Von Storch SE Sells 56,403 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Flossbach Von Storch SE cut its stake in IDEXX by 51% in Q4, selling 56,403 shares and leaving it with 54,131 shares (about 0.07% of the company) valued at roughly $36.62 million.
• Company insiders sold a total of 45,957 shares over the past three months (about $29.86 million), leaving insiders with approximately 0.79% ownership.
• Analysts have trimmed targets recently but the stock retains a consensus rating of "Moderate Buy" with an average price target of $760, supported by the company’s recent beat on quarterly EPS and FY2026 guidance of $14.29–$14.80.

Flossbach Von Storch SE lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 51.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,131 shares of the company's stock after selling 56,403 shares during the quarter. Flossbach Von Storch SE owned about 0.07% of IDEXX Laboratories worth $36,621,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in IDXX. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $29,000. J.Safra Asset Management Corp bought a new position in shares of IDEXX Laboratories during the third quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company's stock worth $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the third quarter valued at $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on IDXX. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price on the stock. Barclays decreased their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $760.00.

IDEXX Laboratories Stock Up 1.6%

Shares of NASDAQ IDXX opened at $574.95 on Tuesday. The firm's 50-day moving average price is $593.73 and its 200-day moving average price is $652.77. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $45.67 billion, a price-to-earnings ratio of 43.99, a P/E/G ratio of 3.44 and a beta of 1.72. IDEXX Laboratories, Inc. has a 12-month low of $427.70 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $2.53 earnings per share. The firm's revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.